Targets › IDS
5 programs from 4 companies in 7 trials: 4 Phase 2, 2 Phase 1, 1 Phase 3; Metabolic and endocrine; next expected readout Jun 2027.
Lysosomal enzyme involved in the degradation pathway of dermatan sulfate and heparan sulfate. (UniProt, P22304)
Open in Phaseline: the race on IDS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| REGENXBIO | RGX-121-3102 Recombinant adeno-associated virus serotype 9 (AAV9) delivering human iduronate-2-sulfatas | IDS | Phase 3 | MPS II; Mucopolysaccharidosis Type II (MPS II) | Apr 2028 |
| Denali Therapeutics | tividenofusp alfa (DNL310) CNS-penetrant iduronate 2-sulfatase enzyme replacement therapy | IDS | Phase 2 | Mucopolysaccharidosis II | Dec 2027 |
| Takeda | Elaprase Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intravenously | IDS | Phase 2 | Hunter Syndrome | Jan 2029 |
| Takeda | Idursulfase-IT Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intrathecally | IDS | Phase 2 | Hunter Syndrome | Jan 2029 |
| GC Biopharma | GC1123 Idursulfase-β (Hunter syndrome enzyme replacement therapy) | IDS | Phase 1 | Mucopolysaccharidosis II | Jun 2027 |
Mucopolysaccharidosis II (3) Hunter Syndrome (2) MPS II (1) Mucopolysaccharidosis Type II (MPS II) (1)
protein or peptide (3), mixed (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.